Bausch Company Profile

What is the competitive landscape for BAUSCH

BAUSCH has one hundred and seventy-eight approved drugs.

There are one hundred and sixteen US patents protecting BAUSCH drugs.

There are seven hundred and seventy-nine patent family members on BAUSCH drugs in fifty-three countries and two hundred and fourteen supplementary protection certificates in sixteen countries.

Summary for Bausch

International Patents:	779
US Patents:	116
Tradenames:	156
Ingredients:	122
NDAs:	178
Patent Litigation for Bausch:	See patent lawsuits for Bausch

Drugs and US Patents for Bausch

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb	ALAWAY	ketotifen fumarate	SOLUTION/DROPS;OPHTHALMIC	021996-001	Dec 1, 2006		OTC	Yes	Yes
Bausch	DEMSER	metyrosine	CAPSULE;ORAL	017871-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes
Bausch And Lomb	FLURBIPROFEN SODIUM	flurbiprofen sodium	SOLUTION/DROPS;OPHTHALMIC	074447-001	Jan 4, 1995		RX	No	Yes
Bausch	NUTRACORT	hydrocortisone	CREAM;TOPICAL	080442-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Bausch	VIRAZOLE	ribavirin	FOR SOLUTION;INHALATION	018859-001	Dec 31, 1985	AN	RX	Yes	Yes
Bausch	ZELAPAR	selegiline hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	021479-001	Jun 14, 2006		RX	Yes	Yes

Expired US Patents for Bausch

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch	CARDIZEM LA	diltiazem hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021392-005	Feb 6, 2003	5,529,791
Bausch	METROGEL-VAGINAL	metronidazole	GEL;VAGINAL	020208-001	Aug 17, 1992	4,837,378
Bausch	MIGRANAL	dihydroergotamine mesylate	SPRAY, METERED;NASAL	020148-001	Dec 8, 1997	4,462,983
Bausch And Lomb	RETISERT	fluocinolone acetonide	IMPLANT;INTRAVITREAL	021737-001	Apr 8, 2005	6,548,078
Bausch	TIAZAC	diltiazem hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020401-002	Sep 11, 1995	5,529,791
Bausch	VASERETIC	enalapril maleate; hydrochlorothiazide	TABLET;ORAL	019221-001	Oct 31, 1986	4,472,380*PED

Paragraph IV (Patent) Challenges for BAUSCH drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Capsules	75 mg		2011-06-06
	Vaginal Gel	0.75%		2004-09-02
	Cream	5%		2006-10-17
	Topical Solution	10%		2018-06-06
	Cream	0.10%		2008-01-31
	Extended-release Tablets	348 mg		2009-09-24
	Cream	2.5%		2014-06-17
	Extended-release Tablets	120 mg, 180 mg, 240 mg, 300 mg and 360 mg		2005-08-30
	Rectal Gel	2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL, 15 mg/3 mL and 20 mg/4 mL		2004-03-23
	Extended-release Tablets	65 mg and 115 mg		2009-11-19
	Rectal Gel	5 mg/mL, 2mL pre-filled syringe		2008-12-23
	Extended-release Tablet	105 rng		2010-12-28
	Gel	1.2%/3.75%		2015-09-30
	Ophthalmic Solution	0.5%		2012-10-19
	Gel	0.04%		2010-12-20
	Ophthalmic Solution	1.5%		2013-09-09
	Gel	1.2%/0.025%		2010-12-17
	Gel	0.77%		2006-05-10
	Lotion	0.1%		2016-08-31
	Extended-release Tablets	174 mg		2009-09-28
	Cream	3.75%		2012-08-08
	Extended-release Tablets	522 mg		2009-12-24
	For Inhalation Solution	6 gm/vial		2014-05-22
	Extended-release Tablets	420 mg		2005-04-25
	Rectal Gel	5 mg/mL, 4mL pre-filled syringe		2008-12-08
	Extended-release Tablet	55 mg and 80 mg		2010-12-02
	Gel	1.2%/2.5%		2012-12-20
	Extended-release Tablets	150 mg and 300 mg		2004-09-21
	Gel	0.1%		2010-07-08
	Ophthalmic Solution	0.07%		2013-07-26

International Patents for Bausch Drugs

Country	Patent Number	Estimated Expiration
Canada	3149296
Japan	2013542990
Poland	3488847
Singapore	11201602596U
South Korea	102282973
South Korea	20210032571

Supplementary Protection Certificates for Bausch Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1259550	08C0052	France		PRODUCT NAME: SUGAMMADEX SODIUM; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
0268956	1999C0030	Belgium		PRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508
1280520	300722	Netherlands		PRODUCT NAME: TOBRAMYCINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: C(2011)5394 20110720
0364417	9690031-1	Sweden		PRODUCT NAME: LATANOPROST
2666774	CR 2020 00037	Denmark		PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217
1304992	PA2013025,C1304992	Lithuania		PRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Bausch
• Bausch And Lomb
• Bausch And Lomb Inc
• Bausch Lomb Ireland

Pharmaceutical Competitive Landscape Analysis: Bausch Health's Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, Bausch Health has emerged as a significant player, carving out a unique position for itself. This comprehensive analysis delves into Bausch Health's market standing, competitive advantages, and strategic direction, offering valuable insights for industry professionals and investors alike.

Bausch Health's Market Position

Bausch Health has established a strong foothold in the pharmaceutical market, particularly in the fields of neurology, dermatology, and infectious diseases. As of February 2025, the company reported a market capitalization of CAD 3.79 billion, reflecting its substantial presence in the industry[1].

Market Share and Competitive Standing

According to recent data from Q3 2024, Bausch Health held a market share of 1.73% in its sector, showcasing its competitive position among industry giants[4]. While this may seem modest, it's important to note that the pharmaceutical market is highly fragmented, with numerous players vying for market share.

"Bausch Health's market position is built on a foundation of innovation, quality, and patient-centric care. By staying at the forefront of medical research and maintaining a strong focus on meeting the needs of patients, Bausch Health has established itself as a leader in the pharmaceutical industry."[3]

Key Strengths of Bausch Health

Diverse Product Portfolio

One of Bausch Health's primary strengths lies in its diverse product portfolio. The company offers a wide range of medications across various therapeutic areas, allowing it to cater to multiple market segments and reduce dependency on any single product line[3].

Strong R&D Capabilities

Bausch Health's commitment to research and development is evident in its substantial R&D investments. In 2021, the company allocated approximately $465 million to R&D, representing about 6% of its revenue[2]. This focus on innovation helps Bausch Health maintain its competitive edge and continually bring new products to market.

Global Presence

With operations spanning multiple countries, Bausch Health benefits from a strong global presence. This international footprint allows the company to tap into diverse markets and mitigate risks associated with regional economic fluctuations[3].

Strategic Initiatives and Future Outlook

Focus on Core Therapeutic Areas

Bausch Health has strategically aligned its business to focus on core therapeutic areas with attractive growth opportunities. This approach has simplified operations and increased the value of key business segments, including eye health, gastrointestinal, and dermatology[2].

Expansion into Emerging Markets

The company is actively exploring opportunities to expand its presence in emerging markets. This strategy aims to capitalize on the growing demand for healthcare products in these regions and diversify revenue streams[3].

Digital Health Initiatives

Recognizing the increasing importance of digital health technologies, Bausch Health is investing in telemedicine, remote patient monitoring, and digital therapeutics. These initiatives are expected to enhance patient care and improve treatment outcomes[3].

Competitive Challenges and Industry Trends

Intense Market Competition

Bausch Health operates in a highly competitive market, facing stiff competition from both established pharmaceutical giants and emerging players. As of 2024, the company had approximately 127 direct competitors in the pharmaceutical and generic drug sectors[9].

Patent Expirations

Like many pharmaceutical companies, Bausch Health faces challenges related to patent expirations. Key products such as Xifaxan and Wellbutrin XL are approaching patent expiration, potentially impacting future revenues[9].

Regulatory Environment

The pharmaceutical industry is subject to stringent regulations, and compliance costs are on the rise. Bausch Health's regulatory compliance expenses increased by 22% in 2023, with projected costs reaching $124 million in 2024[9].

Financial Performance and Outlook

Recent Financial Results

In the fourth quarter of 2023, Bausch Health reported total revenue of $1.173 billion, representing an 18% increase compared to the same period in 2022. For the full year 2023, revenue reached $4.146 billion, growing 10% year-over-year[10].

Segment Performance

Bausch Health's revenue growth in 2023 was driven by strong performance across all segments:

• Vision Care: 6% growth in Q4 2023
• Surgical: 9% growth in Q4 2023
• Pharmaceuticals: 67% growth in Q4 2023[10]

2024 Guidance

While specific guidance for 2024 was not provided in the available information, the company's strong performance in 2023 sets a positive tone for the future. CEO Brent Saunders stated, "Revenue growth in 2023, and in the fourth quarter in particular, exceeded our expectations and set the tone for 2024."[10]

Strategic Partnerships and Collaborations

Bausch Health recognizes the value of strategic partnerships in driving innovation and growth. The company has formed alliances with other pharmaceutical firms, research institutions, and healthcare organizations to enhance its product portfolio and expand market reach[3].

Sustainability and Corporate Social Responsibility

In line with growing consumer expectations, Bausch Health is placing increased emphasis on sustainability and corporate social responsibility. The company is implementing sustainable practices and supporting community initiatives to enhance its brand reputation and contribute positively to society[3].

Key Takeaways

• Bausch Health holds a significant position in the pharmaceutical market, with a diverse product portfolio and strong R&D capabilities.
• The company's focus on core therapeutic areas and expansion into emerging markets positions it for future growth.
• Challenges include intense competition, patent expirations, and increasing regulatory compliance costs.
• Strong financial performance in 2023 sets a positive tone for 2024 and beyond.
• Strategic partnerships and a focus on sustainability are key elements of Bausch Health's long-term strategy.

FAQs

1. What are Bausch Health's main therapeutic areas? Bausch Health focuses primarily on neurology, dermatology, and infectious diseases.

2. How much does Bausch Health invest in R&D? In 2021, Bausch Health invested approximately $465 million in R&D, representing about 6% of its revenue.

3. What is Bausch Health's market share? As of Q3 2024, Bausch Health held a market share of 1.73% in its sector.

4. How has Bausch Health's revenue grown recently? In Q4 2023, Bausch Health's revenue grew 18% year-over-year, while full-year 2023 revenue increased by 10%.

5. What are the main challenges facing Bausch Health? Key challenges include intense market competition, patent expirations for key products, and increasing regulatory compliance costs.

Sources cited: [1] https://tradingeconomics.com/vrx:cn:market-capitalization [2] https://market.us/statistics/pharmaceutical-industry/bausch-health/ [3] https://canvasbusinessmodel.com/blogs/competitors/bausch-health-competitive-landscape [4] https://csimarket.com/stocks/competitionSEG2.php?code=BHC [9] https://dcfmodeling.com/products/bhc-swot-analysis [10] https://ir.bausch.com/press-releases/bausch-lomb-announces-fourth-quarter-and-full-year-2023-results-and-provides-2024